Search

Your search keyword '"Lamerz, A."' showing total 787 results

Search Constraints

Start Over You searched for: Author "Lamerz, A." Remove constraint Author: "Lamerz, A."
787 results on '"Lamerz, A."'

Search Results

1. Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Male Mice

3. Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Mice

4. Pre- and perinatal complications in relation to Tourette syndrome and co-occurring obsessive-compulsive disorder and attention-deficit/hyperactivity disorder

7. De Novo Coding Variants Are Strongly Associated with Tourette Disorder

8. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers

9. Supplementary Figure 1 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines

10. Supplementary Table 1 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines

11. Data from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines

12. Supplementary Figure 2 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines

13. Supplementary Methods from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines

16. Impact of non-ionizable lipids and phase mixing methods on structural properties of lipid nanoparticle formulations

18. Supplementary Figure 2 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines

19. Supplementary Figure 1 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines

20. Data from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines

22. Data from Methylation of Serum DNA Is an Independent Prognostic Marker in Colorectal Cancer

24. Severe Multiorgan Failure Following Yellow Fever Vaccination

27. Automated Sample Preparation Platform for Mass Spectrometry-Based Plasma Proteomics and Biomarker Discovery

28. Poster

32. An Improved Impact Ratio for Identifying Critical Process Parameters in Pharmaceutical Manufacturing Processes

34. Prevalence of Obesity, Binge Eating, and Night Eating in a Cross-Sectional Field Survey of 6-Year-Old Children and Their Parents in a German Urban Population

36. Tumormarker

49. Severe Multiorgan Failure Following Yellow Fever Vaccination

50. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort.

Catalog

Books, media, physical & digital resources